AG˹ٷ

STOCK TITAN

[424B2] Morgan Stanley Prospectus Supplement

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
424B2
Rhea-AI Filing Summary

Citigroup Global Markets Holdings Inc., guaranteed by Citigroup Inc., is issuing $10 million of Autocallable Phoenix Securities linked to Thermo Fisher Scientific Inc. (TMO) common stock. Each $1,000 note may pay a contingent monthly coupon of 1.4667% (�17.60% annualised) if, on the relevant valuation date, TMO closes at or above the coupon barrier of 85% of the initial share price ($347.038).

  • Automatic early redemption: If TMO � initial share price ($408.28) on any of the 11 interim dates, investors receive $1,000 plus the current coupon (including any previously missed payments) and the note terminates.
  • Downside risk: If not redeemed and TMO closes below the final barrier (also 85% of initial price) on 30 Jun 2026, principal is reduced by 117.647% of the decline beyond the 15% buffer, exposing investors to losses up to 100%.
  • No upside participation: Investors do not benefit from TMO price appreciation beyond coupons and forgo dividends.
  • Pricing & liquidity: Issue price is $1,000; estimated value is $992.70. Notes are unlisted; secondary market, if any, will be made solely by CGMI at its discretion.
  • Credit & structural risks: Payments depend on the credit of Citigroup Global Markets Holdings Inc. and Citigroup Inc. Complex tax treatment remains uncertain; withholding of 30% may apply to non-U.S. holders.
The product targets yield-seeking investors who can tolerate equity-linked downside, limited liquidity and issuer credit risk in exchange for potentially high coupons and an early redemption feature.

Citigroup Global Markets Holdings Inc., garantita da Citigroup Inc., emette 10 milioni di dollari di Autocallable Phoenix Securities legati alle azioni ordinarie di Thermo Fisher Scientific Inc. (TMO). Ogni nota da 1.000 dollari può pagare un coupon mensile condizionato dell'1,4667% (circa il 17,60% annuo) se, alla data di valutazione rilevante, il prezzo di chiusura di TMO è pari o superiore alla barriera del coupon fissata all'85% del prezzo iniziale delle azioni (347,038 $).

  • Rimborso anticipato automatico: Se TMO è � al prezzo iniziale delle azioni (408,28 $) in una delle 11 date intermedie, gli investitori ricevono 1.000 $ più il coupon corrente (inclusi eventuali pagamenti mancati precedenti) e la nota termina.
  • Rischio di ribasso: Se non viene rimborsata e TMO chiude al di sotto della barriera finale (anch’essa l�85% del prezzo iniziale) il 30 giugno 2026, il capitale viene ridotto del 117,647% della perdita oltre la soglia del 15%, esponendo gli investitori a perdite fino al 100%.
  • Nessuna partecipazione al rialzo: Gli investitori non beneficiano dell’apprezzamento del prezzo di TMO oltre ai coupon e rinunciano ai dividendi.
  • Prezzo e liquidità: Prezzo di emissione 1.000 $; valore stimato 992,70 $. Le note sono non quotate; il mercato secondario, se presente, sarà gestito esclusivamente da CGMI a sua discrezione.
  • Rischi di credito e strutturali: I pagamenti dipendono dalla solidità creditizia di Citigroup Global Markets Holdings Inc. e Citigroup Inc. Il trattamento fiscale è complesso e incerto; potrebbe applicarsi una ritenuta del 30% per i detentori non statunitensi.
Il prodotto è destinato a investitori alla ricerca di rendimento che possano tollerare il rischio di ribasso legato all’equity, la liquidità limitata e il rischio di credito dell’emittente in cambio di coupon potenzialmente elevati e della possibilità di rimborso anticipato.

Citigroup Global Markets Holdings Inc., garantizado por Citigroup Inc., emite 10 millones de dólares en Autocallable Phoenix Securities vinculados a las acciones comunes de Thermo Fisher Scientific Inc. (TMO). Cada nota de 1.000 dólares puede pagar un cupón mensual contingente del 1,4667% (aproximadamente 17,60% anualizado) si, en la fecha de valoración correspondiente, TMO cierra igual o por encima de la barrera del cupón del 85% del precio inicial de la acción (347,038 $).

  • Redención anticipada automática: Si TMO � precio inicial de la acción (408,28 $) en cualquiera de las 11 fechas intermedias, los inversores reciben 1.000 $ más el cupón actual (incluyendo pagos pendientes anteriores) y la nota termina.
  • Riesgo a la baja: Si no se redime y TMO cierra por debajo de la barrera final (también 85% del precio inicial) el 30 de junio de 2026, el principal se reduce en un 117,647% de la caída más allá del colchón del 15%, exponiendo a los inversores a pérdidas de hasta el 100%.
  • Sin participación en la subida: Los inversores no se benefician de la apreciación del precio de TMO más allá de los cupones y renuncian a los dividendos.
  • Precio y liquidez: Precio de emisión 1.000 $; valor estimado 992,70 $. Las notas son no cotizadas; el mercado secundario, si existe, será gestionado exclusivamente por CGMI a su discreción.
  • Riesgos de crédito y estructurales: Los pagos dependen del crédito de Citigroup Global Markets Holdings Inc. y Citigroup Inc. El tratamiento fiscal es complejo e incierto; podría aplicarse una retención del 30% para tenedores no estadounidenses.
El producto está dirigido a inversores que buscan rendimiento y pueden tolerar el riesgo a la baja vinculado a acciones, liquidez limitada y riesgo crediticio del emisor a cambio de cupones potencialmente altos y la función de redención anticipada.

Citigroup Global Markets Holdings Inc.(시티그룹 Inc. 보증)� Thermo Fisher Scientific Inc.(TMO) 보통주에 연계� 1,000� 달러 규모� Autocallable Phoenix Securities� 발행합니�. � 1,000달러 어음은 해당 평가일에 TMO가 초기 주가($347.038)� 85%� 쿠폰 장벽 이상으로 마감� 경우 월별 조건부 쿠폰 1.4667%(연환� � 17.60%)� 지급할 � 있습니다.

  • 자동 조기 상환: 11번의 중간 평가� � 어느 날이라도 TMO가 초기 주가($408.28) 이상� 경우, 투자자는 1,000달러와 현재 쿠폰(이전 미지� 쿠폰 포함)� 받고 어음은 종료됩니�.
  • 하락 위험: 상환되지 않고 2026� 6� 30일에 TMO가 최종 장벽(초기 가격의 85%) 아래� 마감하면, 원금은 15% 완충 구간� 초과� 하락분의 117.647%만큼 감소하며, 투자자는 최대 100% 손실 위험� 노출됩니�.
  • 상승 참여 없음: 투자자는 쿠폰 외에 TMO 주가 상승� 이익� 누리지 못하� 배당금도 받지 못합니다.
  • 가� � 유동�: 발행 가격은 1,000달러이며, 추정 가치는 992.70달러입니�. 어음은 ѫ�이며, 2� 시장� 존재� 경우 CGMI가 단독 재량으로 운영합니�.
  • 신용 � 구조� 위험: 지급은 Citigroup Global Markets Holdings Inc. � Citigroup Inc.� 신용 상태� 따라 달라집니�. 세금 처리 방식은 복잡하며 불확실하�, 미국 � 투자자에게는 30% 원천징수가 적용� � 있습니다.
� 상품은 주식 연계 하락 위험, 제한� 유동� � 발행� 신용 위험� 감수� � 있는 수익 추구 투자자를 대상으� 하며, 잠재적으� 높은 쿠폰� 조기 상환 기능� 제공합니�.

Citigroup Global Markets Holdings Inc., garanti par Citigroup Inc., émet 10 millions de dollars de Autocallable Phoenix Securities liés aux actions ordinaires de Thermo Fisher Scientific Inc. (TMO). Chaque note de 1 000 $ peut verser un coupon mensuel conditionnel de 1,4667% (�17,60% annualisé) si, à la date d’évaluation pertinente, le cours de clôture de TMO est égal ou supérieur à la barrière du coupon fixée à 85% du prix initial de l’action (347,038 $).

  • Remboursement anticipé automatique : Si TMO � prix initial de l’action (408,28 $) à l’une des 11 dates intermédiaires, les investisseurs reçoivent 1 000 $ plus le coupon actuel (y compris tout paiement manqué antérieur) et la note prend fin.
  • Risque à la baisse : Si elle n’est pas remboursée et que TMO clôture en dessous de la barrière finale (également 85% du prix initial) le 30 juin 2026, le principal est réduit de 117,647% de la baisse au-delà de la marge de 15%, exposant les investisseurs à des pertes pouvant atteindre 100%.
  • Pas de participation à la hausse : Les investisseurs ne bénéficient pas de l’appréciation du cours de TMO au-delà des coupons et renoncent aux dividendes.
  • Prix et liquidité : Prix d’émission 1 000 $ ; valeur estimée 992,70 $. Les notes sont non cotées ; le marché secondaire, s’il existe, sera géré uniquement par CGMI à sa discrétion.
  • Risques de crédit et structurels : Les paiements dépendent de la solvabilité de Citigroup Global Markets Holdings Inc. et de Citigroup Inc. Le traitement fiscal est complexe et incertain ; une retenue à la source de 30% peut s’appliquer aux détenteurs non américains.
Ce produit cible les investisseurs à la recherche de rendement capables de tolérer un risque de baisse lié aux actions, une liquidité limitée et un risque de crédit émetteur en échange de coupons potentiellement élevés et d’une option de remboursement anticipé.

Citigroup Global Markets Holdings Inc., garantiert durch Citigroup Inc., gibt 10 Millionen US-Dollar an Autocallable Phoenix Securities aus, die an die Stammaktien von Thermo Fisher Scientific Inc. (TMO) gekoppelt sind. Jede 1.000-Dollar-Note kann einen bedingten monatlichen Kupon von 1,4667% (�17,60% p.a.) zahlen, wenn TMO am jeweiligen Bewertungstag auf oder über der Kupon-Barriere von 85% des Anfangskurses (347,038 $) schließt.

  • Automatische vorzeitige Rückzahlung: Wenn TMO an einem der 11 Zwischentermine � Anfangskurs (408,28 $) schließt, erhalten Investoren 1.000 $ plus den aktuellen Kupon (einschließlich aller zuvor ausgefallenen Zahlungen) und die Note endet.
  • äٲ: Wird nicht zurückgezahlt und schließt TMO am 30. Juni 2026 unter der Endbarriere (ebenfalls 85% des Anfangskurses), wird der Kapitalbetrag um 117,647% des Rückgangs über den 15% Puffer hinaus reduziert, was Verluste von bis zu 100% für Investoren bedeutet.
  • Keine Aufwärtsteilnahme: Investoren profitieren nicht von Kurssteigerungen über die Kupons hinaus und verzichten auf Dividenden.
  • Preis & Liquidität: Ausgabepreis 1.000 $; geschätzter Wert 992,70 $. Die Notes sind nicht börsennotiert; ein Sekundärmarkt, falls vorhanden, wird ausschließlich von CGMI nach eigenem Ermessen bereitgestellt.
  • Kredit- & Strukturierungsrisiken: Zahlungen hängen von der Bonität von Citigroup Global Markets Holdings Inc. und Citigroup Inc. ab. Die steuerliche Behandlung ist komplex und unsicher; für Nicht-US-Inhaber kann eine Quellensteuer von 30% anfallen.
Das Produkt richtet sich an renditeorientierte Anleger, die ein aktienbezogenes Abwärtsrisiko, eingeschränkte Liquidität und Emittenten-Kreditrisiken tolerieren können, um potenziell hohe Kupons und eine vorzeitige Rückzahlungsfunktion zu erhalten.

Positive
  • High potential income: 1.4667% monthly (�17.6% annualised) contingent coupon exceeds conventional Citi debt of similar maturity.
  • 15% downside buffer: Partial protection against moderate declines in TMO before principal is impaired.
  • Early redemption feature: Can lock in coupons and principal in as little as one month if TMO trades at or above the strike.
  • Low underwriting fee: 0.10% fee lowers embedded costs relative to many retail structured notes.
  • Parent guarantee: Payments are fully and unconditionally guaranteed by Citigroup Inc., adding an additional credit layer.
Negative
  • No upside participation: Investors forgo all appreciation in TMO beyond fixed coupons.
  • Magnified downside after buffer: Losses exceed underlying decline once 15% threshold is breached (117.647% participation).
  • Contingent coupons: Income stops whenever TMO closes below 85% barrier; missed coupons may never be recovered.
  • Early call reinvestment risk: Automatic redemption limits maximum coupon accrual and may occur during low-rate periods.
  • Illiquidity: Unlisted security; secondary market solely at CGMI’s discretion and likely at a discount.
  • Estimated value below issue price: $992.70 vs $1,000 highlights embedded costs and negative carry at inception.
  • Complex tax treatment: Uncertain IRS classification; potential 30% withholding for non-U.S. holders.
  • Issuer/guarantor credit exposure: Principal and coupons subject to Citi credit risk, unlike direct equity ownership.

Insights

TL;DR � High coupons offset by contingent nature, magnified downside past 15% buffer and no upside; neutral risk-reward.

The note offers headline coupons of 17.6% p.a. and a 15% buffer, attractive in today’s rate environment. However, coupons stop whenever TMO trades below the 85% barrier, and missed payments only accrue if the barrier is later breached on the upside. Downside is leveraged 1.176× once the buffer is pierced, meaning a 30% decline in TMO cuts principal by ~35.3%. Investors sacrifice all price appreciation beyond coupon receipts and face early-call reinvestment risk. The $992.70 estimated value implies a 0.73% issue premium after accounting for a modest $1 (0.1%) underwriting fee. Illiquidity and credit exposure to Citi further temper appeal. Overall the structure suits tactical income investors with a stable-to-moderately-bullish view on TMO over the next 12 months but is inappropriate for buy-and-hold equity participants.

TL;DR � Adds yield but low notional ($10 m) and callable nature make it immaterial for Citi; risky for retail allocators.

From an issuer standpoint, the $10 million tranche is de minimis funding that marginally diversifies Citi’s liability mix. For portfolio construction, the note behaves like short put exposure on TMO with capped income. Correlation to core fixed income is low, but downside aligns with equity beta, eroding diversification benefits. The call schedule heavily skews outcomes toward early redemption, creating reinvestment drag in stable-to-rising equity scenarios. Given TMO’s realised 30-day volatility (~23%) and an 85% barrier, Monte-Carlo scenarios suggest ~45-50% probability of zero principal loss but only ~18-20% probability of collecting full coupon stream. Thus, risk-adjusted expected return is modest. Liquidity constraints and adverse tax positioning further limit institutional appetite.

Citigroup Global Markets Holdings Inc., garantita da Citigroup Inc., emette 10 milioni di dollari di Autocallable Phoenix Securities legati alle azioni ordinarie di Thermo Fisher Scientific Inc. (TMO). Ogni nota da 1.000 dollari può pagare un coupon mensile condizionato dell'1,4667% (circa il 17,60% annuo) se, alla data di valutazione rilevante, il prezzo di chiusura di TMO è pari o superiore alla barriera del coupon fissata all'85% del prezzo iniziale delle azioni (347,038 $).

  • Rimborso anticipato automatico: Se TMO è � al prezzo iniziale delle azioni (408,28 $) in una delle 11 date intermedie, gli investitori ricevono 1.000 $ più il coupon corrente (inclusi eventuali pagamenti mancati precedenti) e la nota termina.
  • Rischio di ribasso: Se non viene rimborsata e TMO chiude al di sotto della barriera finale (anch’essa l�85% del prezzo iniziale) il 30 giugno 2026, il capitale viene ridotto del 117,647% della perdita oltre la soglia del 15%, esponendo gli investitori a perdite fino al 100%.
  • Nessuna partecipazione al rialzo: Gli investitori non beneficiano dell’apprezzamento del prezzo di TMO oltre ai coupon e rinunciano ai dividendi.
  • Prezzo e liquidità: Prezzo di emissione 1.000 $; valore stimato 992,70 $. Le note sono non quotate; il mercato secondario, se presente, sarà gestito esclusivamente da CGMI a sua discrezione.
  • Rischi di credito e strutturali: I pagamenti dipendono dalla solidità creditizia di Citigroup Global Markets Holdings Inc. e Citigroup Inc. Il trattamento fiscale è complesso e incerto; potrebbe applicarsi una ritenuta del 30% per i detentori non statunitensi.
Il prodotto è destinato a investitori alla ricerca di rendimento che possano tollerare il rischio di ribasso legato all’equity, la liquidità limitata e il rischio di credito dell’emittente in cambio di coupon potenzialmente elevati e della possibilità di rimborso anticipato.

Citigroup Global Markets Holdings Inc., garantizado por Citigroup Inc., emite 10 millones de dólares en Autocallable Phoenix Securities vinculados a las acciones comunes de Thermo Fisher Scientific Inc. (TMO). Cada nota de 1.000 dólares puede pagar un cupón mensual contingente del 1,4667% (aproximadamente 17,60% anualizado) si, en la fecha de valoración correspondiente, TMO cierra igual o por encima de la barrera del cupón del 85% del precio inicial de la acción (347,038 $).

  • Redención anticipada automática: Si TMO � precio inicial de la acción (408,28 $) en cualquiera de las 11 fechas intermedias, los inversores reciben 1.000 $ más el cupón actual (incluyendo pagos pendientes anteriores) y la nota termina.
  • Riesgo a la baja: Si no se redime y TMO cierra por debajo de la barrera final (también 85% del precio inicial) el 30 de junio de 2026, el principal se reduce en un 117,647% de la caída más allá del colchón del 15%, exponiendo a los inversores a pérdidas de hasta el 100%.
  • Sin participación en la subida: Los inversores no se benefician de la apreciación del precio de TMO más allá de los cupones y renuncian a los dividendos.
  • Precio y liquidez: Precio de emisión 1.000 $; valor estimado 992,70 $. Las notas son no cotizadas; el mercado secundario, si existe, será gestionado exclusivamente por CGMI a su discreción.
  • Riesgos de crédito y estructurales: Los pagos dependen del crédito de Citigroup Global Markets Holdings Inc. y Citigroup Inc. El tratamiento fiscal es complejo e incierto; podría aplicarse una retención del 30% para tenedores no estadounidenses.
El producto está dirigido a inversores que buscan rendimiento y pueden tolerar el riesgo a la baja vinculado a acciones, liquidez limitada y riesgo crediticio del emisor a cambio de cupones potencialmente altos y la función de redención anticipada.

Citigroup Global Markets Holdings Inc.(시티그룹 Inc. 보증)� Thermo Fisher Scientific Inc.(TMO) 보통주에 연계� 1,000� 달러 규모� Autocallable Phoenix Securities� 발행합니�. � 1,000달러 어음은 해당 평가일에 TMO가 초기 주가($347.038)� 85%� 쿠폰 장벽 이상으로 마감� 경우 월별 조건부 쿠폰 1.4667%(연환� � 17.60%)� 지급할 � 있습니다.

  • 자동 조기 상환: 11번의 중간 평가� � 어느 날이라도 TMO가 초기 주가($408.28) 이상� 경우, 투자자는 1,000달러와 현재 쿠폰(이전 미지� 쿠폰 포함)� 받고 어음은 종료됩니�.
  • 하락 위험: 상환되지 않고 2026� 6� 30일에 TMO가 최종 장벽(초기 가격의 85%) 아래� 마감하면, 원금은 15% 완충 구간� 초과� 하락분의 117.647%만큼 감소하며, 투자자는 최대 100% 손실 위험� 노출됩니�.
  • 상승 참여 없음: 투자자는 쿠폰 외에 TMO 주가 상승� 이익� 누리지 못하� 배당금도 받지 못합니다.
  • 가� � 유동�: 발행 가격은 1,000달러이며, 추정 가치는 992.70달러입니�. 어음은 ѫ�이며, 2� 시장� 존재� 경우 CGMI가 단독 재량으로 운영합니�.
  • 신용 � 구조� 위험: 지급은 Citigroup Global Markets Holdings Inc. � Citigroup Inc.� 신용 상태� 따라 달라집니�. 세금 처리 방식은 복잡하며 불확실하�, 미국 � 투자자에게는 30% 원천징수가 적용� � 있습니다.
� 상품은 주식 연계 하락 위험, 제한� 유동� � 발행� 신용 위험� 감수� � 있는 수익 추구 투자자를 대상으� 하며, 잠재적으� 높은 쿠폰� 조기 상환 기능� 제공합니�.

Citigroup Global Markets Holdings Inc., garanti par Citigroup Inc., émet 10 millions de dollars de Autocallable Phoenix Securities liés aux actions ordinaires de Thermo Fisher Scientific Inc. (TMO). Chaque note de 1 000 $ peut verser un coupon mensuel conditionnel de 1,4667% (�17,60% annualisé) si, à la date d’évaluation pertinente, le cours de clôture de TMO est égal ou supérieur à la barrière du coupon fixée à 85% du prix initial de l’action (347,038 $).

  • Remboursement anticipé automatique : Si TMO � prix initial de l’action (408,28 $) à l’une des 11 dates intermédiaires, les investisseurs reçoivent 1 000 $ plus le coupon actuel (y compris tout paiement manqué antérieur) et la note prend fin.
  • Risque à la baisse : Si elle n’est pas remboursée et que TMO clôture en dessous de la barrière finale (également 85% du prix initial) le 30 juin 2026, le principal est réduit de 117,647% de la baisse au-delà de la marge de 15%, exposant les investisseurs à des pertes pouvant atteindre 100%.
  • Pas de participation à la hausse : Les investisseurs ne bénéficient pas de l’appréciation du cours de TMO au-delà des coupons et renoncent aux dividendes.
  • Prix et liquidité : Prix d’émission 1 000 $ ; valeur estimée 992,70 $. Les notes sont non cotées ; le marché secondaire, s’il existe, sera géré uniquement par CGMI à sa discrétion.
  • Risques de crédit et structurels : Les paiements dépendent de la solvabilité de Citigroup Global Markets Holdings Inc. et de Citigroup Inc. Le traitement fiscal est complexe et incertain ; une retenue à la source de 30% peut s’appliquer aux détenteurs non américains.
Ce produit cible les investisseurs à la recherche de rendement capables de tolérer un risque de baisse lié aux actions, une liquidité limitée et un risque de crédit émetteur en échange de coupons potentiellement élevés et d’une option de remboursement anticipé.

Citigroup Global Markets Holdings Inc., garantiert durch Citigroup Inc., gibt 10 Millionen US-Dollar an Autocallable Phoenix Securities aus, die an die Stammaktien von Thermo Fisher Scientific Inc. (TMO) gekoppelt sind. Jede 1.000-Dollar-Note kann einen bedingten monatlichen Kupon von 1,4667% (�17,60% p.a.) zahlen, wenn TMO am jeweiligen Bewertungstag auf oder über der Kupon-Barriere von 85% des Anfangskurses (347,038 $) schließt.

  • Automatische vorzeitige Rückzahlung: Wenn TMO an einem der 11 Zwischentermine � Anfangskurs (408,28 $) schließt, erhalten Investoren 1.000 $ plus den aktuellen Kupon (einschließlich aller zuvor ausgefallenen Zahlungen) und die Note endet.
  • äٲ: Wird nicht zurückgezahlt und schließt TMO am 30. Juni 2026 unter der Endbarriere (ebenfalls 85% des Anfangskurses), wird der Kapitalbetrag um 117,647% des Rückgangs über den 15% Puffer hinaus reduziert, was Verluste von bis zu 100% für Investoren bedeutet.
  • Keine Aufwärtsteilnahme: Investoren profitieren nicht von Kurssteigerungen über die Kupons hinaus und verzichten auf Dividenden.
  • Preis & Liquidität: Ausgabepreis 1.000 $; geschätzter Wert 992,70 $. Die Notes sind nicht börsennotiert; ein Sekundärmarkt, falls vorhanden, wird ausschließlich von CGMI nach eigenem Ermessen bereitgestellt.
  • Kredit- & Strukturierungsrisiken: Zahlungen hängen von der Bonität von Citigroup Global Markets Holdings Inc. und Citigroup Inc. ab. Die steuerliche Behandlung ist komplex und unsicher; für Nicht-US-Inhaber kann eine Quellensteuer von 30% anfallen.
Das Produkt richtet sich an renditeorientierte Anleger, die ein aktienbezogenes Abwärtsrisiko, eingeschränkte Liquidität und Emittenten-Kreditrisiken tolerieren können, um potenziell hohe Kupons und eine vorzeitige Rückzahlungsfunktion zu erhalten.

Pricing Supplement No. 9,137

Registration Statement Nos. 333-275587; 333-275587-01

Dated June 30, 2025

Filed pursuant to Rule 424(b)(2)

Morgan Stanley Finance LLC

Structured Investments

Dual Directional Trigger PLUS due July 5, 2030

Based on the Worst Performing of the S&P 500® Index and the Nasdaq-100 Index®

Trigger Performance Leveraged Upside SecuritiesSM

Fully and Unconditionally Guaranteed by Morgan Stanley

Principal at Risk Securities

The Dual Directional Trigger PLUS (the “securities”) are unsecured obligations of Morgan Stanley Finance LLC (“MSFL”) and are fully and unconditionally guaranteed by Morgan Stanley. The securities will pay no interest, do not guarantee any return of principal at maturity and have the terms described in the accompanying product supplement, index supplement and prospectus, as supplemented or modified by this document.

Payment at maturity. At maturity, if the final level of each underlier is greater than its initial level, investors will receive the stated principal amount plus the leveraged upside payment. If the final level of either underlier is equal to or less than its initial level but the final level of each underlier is greater than or equal to its barrier level, investors will receive at maturity the stated principal amount plus a positive return equal to (i) the absolute value of the percentage decline in the level of the worst performing underlier multiplied by (ii) the absolute return participation rate. If the final level of either underlier is less than the barrier level but the final level of each underlier is greater than or equal to its downside threshold level, investors will receive at maturity the stated principal amount. If, however, the final level of either underlier is less than its downside threshold level, investors will lose 1% for every 1% decline in the level of the worst performing underlier over the term of the securities. Under these circumstances, the payment at maturity will be significantly less than the stated principal amount and could be zero.

The value of the securities is based on the worst performing underlier. The fact that the securities are linked to more than one underlier does not provide any asset diversification benefits and instead means that a decline in the level of either underlier beyond its downside threshold level will adversely affect your return on the securities, even if the other underlier has appreciated or has not declined as much.

The securities are for investors who seek a return based on the performance of the worst performing underlier and who are willing to risk their principal and forgo current income in exchange for the upside leverage feature as well as the absolute return participation feature and the limited protection against loss of principal, each of which applies only to a certain range of negative performance of the worst performing underlier over the term of the securities. Investors in the securities must be willing to accept the risk of losing their entire initial investment based on the performance of either underlier. The securities are notes issued as part of MSFL’s Series A Global Medium-Term Notes program.

All payments are subject to our credit risk. If we default on our obligations, you could lose some or all of your investment. These securities are not secured obligations and you will not have any security interest in, or otherwise have any access to, any underlying reference asset or assets.

FINAL TERMS

Issuer:

Morgan Stanley Finance LLC

Guarantor:

Morgan Stanley

Stated principal amount:

$1,000 per security

Issue price:

$1,000 per security (see “Commissions and issue price” below)

Aggregate principal amount:

$500,000

Underliers:

S&P 500® Index‬ (the “SPX index”) and Nasdaq-100 Index®‬ (the “NDX Index”). We refer to each of the SPX Index and the NDX Index as an underlying index.

Strike date:

June 30, 2025

Pricing date:

June 30, 2025

Original issue date:

July 3, 2025

Observation date:

July 1, 2030, subject to postponement for non-trading days and certain market disruption events

Maturity date:

July 5, 2030

 

Terms continued on the following page

Agent:

Morgan Stanley & Co. LLC (“MS & Co.”), an affiliate of MSFL and a wholly owned subsidiary of Morgan Stanley. See “Supplemental information regarding plan of distribution; conflicts of interest.”

Estimated value on the pricing date:

$972.20 per security. See “Estimated Value of the Securities” on page 3.

Commissions and issue price:

Price to public

Agent’s commissions and fees(1)(2)

Proceeds to us(3)

Per security

$1,000

$7.50

$992.50

Total

$500,000

$3,750

$496,250

(1)The securities will be sold only to investors purchasing the securities in fee-based advisory accounts.

(2)MS & Co. expects to sell all of the securities that it purchases from us to an unaffiliated dealer at a price of $992.50 per security, for further sale to certain fee-based advisory accounts at the price to public of $1,000 per security. MS & Co. will not receive a sales commission with respect to the securities. See “Supplemental information regarding plan of distribution; conflicts of interest.” For additional information, see “Plan of Distribution (Conflicts of Interest)” in the accompanying product supplement.

(3)See “Use of Proceeds and Hedging” in the accompanying product supplement.

The securities involve risks not associated with an investment in ordinary debt securities. See “Risk Factors” beginning on page 6.

The Securities and Exchange Commission and state securities regulators have not approved or disapproved these securities, or determined if this document or the accompanying product supplement, index supplement and prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

The securities are not deposits or savings accounts and are not insured by the Federal Deposit Insurance Corporation or any other governmental agency or instrumentality, nor are they obligations of, or guaranteed by, a bank.

You should read this document together with the related product supplement, index supplement and prospectus, each of which can be accessed via the hyperlinks below. When you read the accompanying index supplement, please note that all references in such supplement to the prospectus dated November 16, 2023, or to any sections therein, should refer instead to the accompanying prospectus dated April 12, 2024 or to the corresponding sections of such prospectus, as applicable. Please also see “Additional Terms of the Securities” and “Additional Information About the Securities” at the end of this document.

References to “we,” “us” and “our” refer to Morgan Stanley or MSFL, or Morgan Stanley and MSFL collectively, as the context requires.

Product Supplement for Principal at Risk Securities dated February 7, 2025 Index Supplement dated November 16, 2023 Prospectus dated April 12, 2024

 

Morgan Stanley Finance LLC

Dual Directional Trigger PLUS

Principal at Risk Securities

 

Terms continued from the previous page

Payment at maturity per security:

If the final level of each underlier is greater than its initial level:

stated principal amount + leveraged upside payment

If the final level of either underlier is equal to or less than its initial level but the final level of each underlier is greater than or equal to its barrier level:

stated principal amount + (stated principal amount × absolute underlier return of the worst performing underlier × absolute return participation rate)

Under these circumstances, the payment at maturity will effectively be limited to a positive return of 25%.

If the final level of either underlier is less than its barrier level but the final level of each underlier is greater than or equal to its downside threshold level:

stated principal amount

If the final level of each underlier is less than its downside threshold level:

stated principal amount × performance factor of the worst performing underlier

Under these circumstances, the payment at maturity will be significantly less than the stated principal amount and could be zero.

Final level:

With respect to each underlier, the closing level on the observation date

Initial level:

With respect to the SPX Index, 6,204.95, which is its closing level on the strike date

With respect to the NDX Index, 22,679.01, which is its closing level on the strike date

Leveraged upside payment:

stated principal amount × leverage factor × underlier percent change of the worst performing underlier

Leverage factor:

108%

Underlier percent change:

With respect to each underlier, (final level – initial level) / initial level

Downside threshold level:

With respect to the SPX Index, 3,102.475, which is 50% of its initial level

With respect to the NDX Index, 11,339.505, which is 50% of its initial level

Barrier level:

With respect to the SPX Index, 4,653.713, which is approximately 75% of its initial level

With respect to the NDX Index, 17,009.258, which is approximately 75% of its initial level

Absolute underlier return:

With respect to each underlier, the absolute value of the underlier percent change. For example, a -5.00% underlier percent change will result in a +5.00% absolute underlier return.

Absolute return participation rate:

100%

Worst performing underlier:

The underlier with the lowest percentage return from its initial level to its final level

Performance factor:

With respect to each underlier, final level / initial level

CUSIP:

61778NEC1

ISIN:

US61778NEC11

Listing:

The securities will not be listed on any securities exchange.

 Page 2

Morgan Stanley Finance LLC

Dual Directional Trigger PLUS

Principal at Risk Securities

 

Estimated Value of the Securities

The original issue price of each security is $1,000. This price includes costs associated with issuing, selling, structuring and hedging the securities, which are borne by you, and, consequently, the estimated value of the securities on the pricing date is less than $1,000. Our estimate of the value of the securities as determined on the pricing date is set forth on the cover of this document.

What goes into the estimated value on the pricing date?

In valuing the securities on the pricing date, we take into account that the securities comprise both a debt component and a performance-based component linked to the underliers. The estimated value of the securities is determined using our own pricing and valuation models, market inputs and assumptions relating to the underliers, instruments based on the underliers, volatility and other factors including current and expected interest rates, as well as an interest rate related to our secondary market credit spread, which is the implied interest rate at which our conventional fixed rate debt trades in the secondary market.

What determines the economic terms of the securities?

In determining the economic terms of the securities, we use an internal funding rate, which is likely to be lower than our secondary market credit spreads and therefore advantageous to us. If the issuing, selling, structuring and hedging costs borne by you were lower or if the internal funding rate were higher, one or more of the economic terms of the securities would be more favorable to you.

What is the relationship between the estimated value on the pricing date and the secondary market price of the securities?

The price at which MS & Co. purchases the securities in the secondary market, absent changes in market conditions, including those related to the underliers, may vary from, and be lower than, the estimated value on the pricing date, because the secondary market price takes into account our secondary market credit spread as well as the bid-offer spread that MS & Co. would charge in a secondary market transaction of this type and other factors. However, because the costs associated with issuing, selling, structuring and hedging the securities are not fully deducted upon issuance, to the extent that MS & Co. may buy or sell the securities in the secondary market during the amortization period specified herein, absent changes in market conditions, including those related to the underliers, and to our secondary market credit spreads, it would do so based on values higher than the estimated value. We expect that those higher values will also be reflected in your brokerage account statements.

MS & Co. may, but is not obligated to, make a market in the securities, and, if it once chooses to make a market, may cease doing so at any time.

 Page 3

Morgan Stanley Finance LLC

Dual Directional Trigger PLUS

Principal at Risk Securities

 

Hypothetical Examples

Hypothetical Payoff Diagram 

The payment at maturity will be based solely on the performance of the worst performing underlier, which could be either underlier. The payoff diagram below illustrates the payment at maturity for a range of hypothetical performances of the worst performing underlier over the term of the securities, based on the following terms:

Stated principal amount:

$1,000 per security

Leverage factor:

108%

Absolute return participation rate:

100%

Downside threshold level:

50% of the initial level

Barrier level:

75% of the initial level

Minimum payment at maturity:

None

Hypothetical Payoff Diagram

 

Upside Scenario. If the final level of the worst performing underlier is greater than its initial level, investors will receive the stated principal amount plus 108% of the appreciation of the worst performing underlier over the term of the securities.

oIf the worst performing underlier appreciates 10%, investors will receive $1,108‬ per security, or 108% of the stated principal amount.

Absolute Return Participation Scenario. If the final level of the worst performing underlier is equal to or less than its initial level but is greater than or equal to its barrier level, investors will receive the stated principal amount plus a positive return equal to (i) the absolute value of the percentage decline in the level of the worst performing underlier multiplied by (ii) the absolute return participation rate. Under these circumstances, the payment at maturity will effectively be limited to a positive return of 25% per security.

oIf the worst performing underlier depreciates 10%, investors will receive $1,100 per security, or 110% of the stated principal amount.

 Page 4

Morgan Stanley Finance LLC

Dual Directional Trigger PLUS

Principal at Risk Securities

 

Par Scenario. If the final level of the worst performing underlier is less than its barrier level but is greater than or equal to its downside threshold level, investors will receive the stated principal amount.

oIf the underlier depreciates 30%, investors will receive $1,000 per security, or 100% of the stated principal amount.

Downside Scenario. If the final level of the worst performing underlier is less than its downside threshold level, investors will receive an amount that is significantly less than the stated principal amount, based on a 1% loss of principal for each 1% decline in the level of the worst performing underlier. There is no minimum payment at maturity, and investors could lose their entire initial investment in the securities.

oIf the worst performing underlier depreciates 85%, investors will lose 85% of their principal and receive only $150 per security at maturity, or 15% of the stated principal amount.

 Page 5

Morgan Stanley Finance LLC

Dual Directional Trigger PLUS

Principal at Risk Securities

 

Risk Factors

This section describes the material risks relating to the securities. For further discussion of these and other risks, you should read the section entitled “Risk Factors” in the accompanying product supplement and prospectus. We also urge you to consult with your investment, legal, tax, accounting and other advisers in connection with your investment in the securities.

Risks Relating to an Investment in the Securities

The securities do not guarantee the return of any principal and do not pay interest. The terms of the securities differ from those of ordinary debt securities in that they do not guarantee the repayment of any principal and do not pay interest. If the final level of either underlier is less than its downside threshold level, the payout at maturity will be an amount in cash that is significantly less than the stated principal amount of each security, and you will lose an amount proportionate to the full decline in the level of the worst performing underlier over the term of the securities. There is no minimum payment at maturity on the securities, and, accordingly, you could lose your entire initial investment in the securities.

Any positive return on the securities that is based on the depreciation of the worst performing underlier is effectively capped. Any positive return on the securities that is based on the depreciation of the worst performing underlier will be capped, because the absolute return participation feature is operative only if the level of the worst performing underlier has not declined below its barrier level on the observation date. Any decline in the level of the worst performing underlier beyond its barrier level will result in no positive return beyond your initial investment in the securities, and any decline in the worst performing underlier beyond its downside threshold level will result in a significant loss, rather than a positive return, on your initial investment in the securities.

The amount payable on the securities is not linked to the values of the underliers at any time other than the observation date. The final levels will be based on the closing levels of the underliers on the observation date, subject to postponement for non-trading days and certain market disruption events. Even if the value of each underlier appreciates prior to the observation date but then the value of either underlier drops by the observation date, the payment at maturity may be significantly less than it would have been had the payment at maturity been linked to the values of the underliers prior to such drop. Although the actual values of the underliers on the stated maturity date or at other times during the term of the securities may be higher than their respective closing levels on the observation date, the payment at maturity will be based solely on the closing levels of the underliers on the observation date.

The market price of the securities may be influenced by many unpredictable factors. Several factors, many of which are beyond our control, will influence the value of the securities in the secondary market and the price at which MS & Co. may be willing to purchase or sell the securities in the secondary market. We expect that generally the value of each underlier at any time will affect the value of the securities more than any other single factor. Other factors that may influence the value of the securities include:

othe volatility (frequency and magnitude of changes in value) of the underliers;

ointerest and yield rates in the market;

othe level of correlation between the underliers;

ogeopolitical conditions and economic, financial, political, regulatory or judicial events that affect the underliers or equity markets generally;

othe availability of comparable instruments;

othe composition of each underlier and changes in the component securities of each underlier;

othe time remaining until the securities mature; and

oany actual or anticipated changes in our credit ratings or credit spreads.

Some or all of these factors will influence the price that you will receive if you sell your securities prior to maturity. Generally, the longer the time remaining to maturity, the more the market price of the securities will be affected by the other factors described above. For example, you may have to sell your securities at a substantial discount from the stated principal amount if, at the time of sale, the closing level of either underlier is at, below or not sufficiently above its downside threshold level, or if market interest rates rise.

You can review the historical closing levels of the underliers in the section of this document called “Historical Information.” You cannot predict the future performance of an underlier based on its historical performance. The values of the underliers may be, and have recently been, volatile, and we can give you no assurance that the volatility will lessen. There can be no assurance that the final level of each underlier will be greater than or equal to its downside threshold level so that you do not suffer a significant loss on your initial investment in the securities.

The securities are subject to our credit risk, and any actual or anticipated changes to our credit ratings or credit spreads may adversely affect the market value of the securities. You are dependent on our ability to pay all amounts due on the

 Page 6

Morgan Stanley Finance LLC

Dual Directional Trigger PLUS

Principal at Risk Securities

 

securities, and, therefore, you are subject to our credit risk. The securities are not guaranteed by any other entity. If we default on our obligations under the securities, your investment would be at risk and you could lose some or all of your investment. As a result, the market value of the securities prior to maturity will be affected by changes in the market’s view of our creditworthiness. Any actual or anticipated decline in our credit ratings or increase in the credit spreads charged by the market for taking our credit risk is likely to adversely affect the market value of the securities.

As a finance subsidiary, MSFL has no independent operations and will have no independent assets. As a finance subsidiary, MSFL has no independent operations beyond the issuance and administration of its securities and will have no independent assets available for distributions to holders of MSFL securities if they make claims in respect of such securities in a bankruptcy, resolution or similar proceeding. Accordingly, any recoveries by such holders will be limited to those available under the related guarantee by Morgan Stanley and that guarantee will rank pari passu with all other unsecured, unsubordinated obligations of Morgan Stanley. Holders will have recourse only to a single claim against Morgan Stanley and its assets under the guarantee. Holders of securities issued by MSFL should accordingly assume that in any such proceedings they would not have any priority over and should be treated pari passu with the claims of other unsecured, unsubordinated creditors of Morgan Stanley, including holders of Morgan Stanley-issued securities.

The rate we are willing to pay for securities of this type, maturity and issuance size is likely to be lower than the rate implied by our secondary market credit spreads and advantageous to us. Both the lower rate and the inclusion of costs associated with issuing, selling, structuring and hedging the securities in the original issue price reduce the economic terms of the securities, cause the estimated value of the securities to be less than the original issue price and will adversely affect secondary market prices. Assuming no change in market conditions or any other relevant factors, the prices, if any, at which dealers, including MS & Co., may be willing to purchase the securities in secondary market transactions will likely be significantly lower than the original issue price, because secondary market prices will exclude the issuing, selling, structuring and hedging-related costs that are included in the original issue price and borne by you and because the secondary market prices will reflect our secondary market credit spreads and the bid-offer spread that any dealer would charge in a secondary market transaction of this type as well as other factors.

The inclusion of the costs of issuing, selling, structuring and hedging the securities in the original issue price and the lower rate we are willing to pay as issuer make the economic terms of the securities less favorable to you than they otherwise would be.

However, because the costs associated with issuing, selling, structuring and hedging the securities are not fully deducted upon issuance, to the extent that MS & Co. may buy or sell the securities in the secondary market during the amortization period specified herein, absent changes in market conditions, including those related to the underliers, and to our secondary market credit spreads, it would do so based on values higher than the estimated value, and we expect that those higher values will also be reflected in your brokerage account statements.

The estimated value of the securities is determined by reference to our pricing and valuation models, which may differ from those of other dealers and is not a maximum or minimum secondary market price. These pricing and valuation models are proprietary and rely in part on subjective views of certain market inputs and certain assumptions about future events, which may prove to be incorrect. As a result, because there is no market-standard way to value these types of securities, our models may yield a higher estimated value of the securities than those generated by others, including other dealers in the market, if they attempted to value the securities. In addition, the estimated value on the pricing date does not represent a minimum or maximum price at which dealers, including MS & Co., would be willing to purchase your securities in the secondary market (if any exists) at any time. The value of your securities at any time after the date of this document will vary based on many factors that cannot be predicted with accuracy, including our creditworthiness and changes in market conditions. See also “The market price of the securities may be influenced by many unpredictable factors” above.

The securities will not be listed on any securities exchange and secondary trading may be limited. The securities will not be listed on any securities exchange. Therefore, there may be little or no secondary market for the securities. MS & Co. may, but is not obligated to, make a market in the securities and, if it once chooses to make a market, may cease doing so at any time. When it does make a market, it will generally do so for transactions of routine secondary market size at prices based on its estimate of the current value of the securities, taking into account its bid/offer spread, our credit spreads, market volatility, the notional size of the proposed sale, the cost of unwinding any related hedging positions, the time remaining to maturity and the likelihood that it will be able to resell the securities. Even if there is a secondary market, it may not provide enough liquidity to allow you to trade or sell the securities easily. Since other broker-dealers may not participate significantly in the secondary market for the securities, the price at which you may be able to trade your securities is likely to depend on the price, if any, at which MS & Co. is willing to transact. If, at any time, MS & Co. were to cease making a market in the securities, it is likely that there would be no secondary market for the securities. Accordingly, you should be willing to hold your securities to maturity.

As discussed in more detail in the accompanying product supplement, investing in the securities is not equivalent to investing in the underlier(s).

The U.S. federal income tax consequences of an investment in the securities are uncertain. There is no direct legal authority regarding the proper U.S. federal income tax treatment of the securities, and significant aspects of the tax treatment of the securities are uncertain. You should review carefully the section entitled “United States Federal Income Tax Considerations”

 Page 7

Morgan Stanley Finance LLC

Dual Directional Trigger PLUS

Principal at Risk Securities

 

herein, in combination with the section entitled “United States Federal Income Tax Considerations” in the accompanying product supplement, and consult your tax adviser regarding the U.S. federal income tax consequences of an investment in the securities.

Risks Relating to the Underlier(s)

Because your return on the securities will depend upon the performance of the underlier(s), the securities are subject to the following risk(s), as discussed in more detail in the accompanying product supplement.

oYou are exposed to the price risk of each underlier.

oBecause the securities are linked to the performance of the worst performing underlier, you are exposed to a greater risk of not receiving a positive return on the securities and/or sustaining a significant loss on your investment than if the securities were linked to just one underlier.

oAdjustments to an underlying index could adversely affect the value of the securities.

Risks Relating to Conflicts of Interest

In engaging in certain activities described below and as discussed in more detail in the accompanying product supplement, our affiliates may take actions that may adversely affect the value of and your return on the securities, and in so doing they will have no obligation to consider your interests as an investor in the securities.

The calculation agent, which is a subsidiary of Morgan Stanley and an affiliate of MSFL, will make determinations with respect to the securities. As calculation agent, MS & Co. will make any determinations necessary to calculate any payment(s) on the securities. Moreover, certain determinations made by MS & Co., in its capacity as calculation agent, may require it to exercise discretion and make subjective judgments, which may adversely affect your return on the securities. In addition, MS & Co. has determined the estimated value of the securities on the pricing date.

Hedging and trading activity by our affiliates could potentially adversely affect the value of the securities.

 Page 8

Morgan Stanley Finance LLC

Dual Directional Trigger PLUS

Principal at Risk Securities

 

Historical Information

S&P 500® Index Overview

Bloomberg Ticker Symbol: SPX

The S&P 500® Index is intended to provide a benchmark for performance measurement of the large capitalization segment of the U.S. equity markets by tracking the stock price movement of 500 companies with large market capitalizations. The underlying index publisher with respect to the S&P 500® Index is S&P® Dow Jones Indices LLC, or any successor thereof. Component stocks of the S&P 500® Index are required to have a total company level market capitalization that reflects approximately the 85th percentile of the S&P® Total Market Index. The S&P 500® Index measures the relative performance of the common stocks of 500 companies as of a particular time as compared to the performance of the common stocks of 500 similar companies during the base period of the years 1941 through 1943. For additional information about the S&P 500® Index, see the information set forth under “S&P® U.S. Indices—S&P 500® Index” in the accompanying index supplement.

The closing level of the SPX Index on June 30, 2025 was 6,204.95. The following graph sets forth the daily closing levels of the underlier for the period noted below. We obtained the historical information presented in this document from Bloomberg Financial Markets, without independent verification. The underlier has at times experienced periods of high volatility. You should not take the historical closing levels of the underlier as an indication of its future performance, and no assurance can be given as to the closing level of the underlier at any time.

SPX Index Daily Closing Levels

January 1, 2020 to June 30, 2025

 

 Page 9

Morgan Stanley Finance LLC

Dual Directional Trigger PLUS

Principal at Risk Securities

 

Nasdaq-100 Index® Overview

Bloomberg Ticker Symbol: NDX

The Nasdaq-100 Index® is a modified capitalization-weighted index of 100 of the largest and most actively traded equity securities of non-financial companies listed on The Nasdaq Stock Market LLC (the “Nasdaq”). The underlying index publisher with respect to the Nasdaq-100 Index® is Nasdaq, Inc., or any successor thereof. The Nasdaq-100 Index® includes companies across a variety of major industry groups. At any moment in time, the value of the Nasdaq-100 Index® equals the aggregate value of the then-current Nasdaq-100 Index® share weights of each of the Nasdaq-100 Index® component securities, which are based on the total shares outstanding of each such Nasdaq-100 Index® component security, multiplied by each such security’s respective last sale price on the Nasdaq (which may be the official closing price published by the Nasdaq), and divided by a scaling factor, which becomes the basis for the reported Nasdaq-100 Index® value. For additional information about the Nasdaq-100 Index®, see the information set forth under “Nasdaq-100 Index®” in the accompanying index supplement.

The closing level of the NDX Index on June 30, 2025 was 22,679.01. The following graph sets forth the daily closing levels of the underlier for the period noted below. We obtained the historical information presented in this document from Bloomberg Financial Markets, without independent verification. The underlier has at times experienced periods of high volatility. You should not take the historical closing levels of the underlier as an indication of its future performance, and no assurance can be given as to the closing level of the underlier at any time.

NDX Index Daily Closing Levels

January 1, 2020 to June 30, 2025

 

 

 

 Page 10

Morgan Stanley Finance LLC

Dual Directional Trigger PLUS

Principal at Risk Securities

 

Additional Terms of the Securities

Please read this information in conjunction with the terms on the cover of this document.

Additional Terms:

If the terms described herein are inconsistent with those described in the accompanying product supplement, index supplement or prospectus, the terms described herein shall control.

Denominations:

$1,000 per security and integral multiples thereof

Dual Directional Trigger PLUS:

The accompanying product supplement refers to these Dual Directional Trigger PLUS as the “securities.”

Amortization period:

The 6-month period following the issue date

Trustee:

The Bank of New York Mellon

Calculation agent:

Morgan Stanley & Co. LLC (“MS & Co.”)

 Page 11

Morgan Stanley Finance LLC

Dual Directional Trigger PLUS

Principal at Risk Securities

 

Additional Information About the Securities

Additional Information:

Minimum ticketing size:

$1,000 / 1 security

United States federal income tax considerations:

You should review carefully the section in the accompanying product supplement entitled “United States Federal Income Tax Considerations.” The following discussion, when read in combination with that section, constitutes the full opinion of our counsel, Davis Polk & Wardwell LLP, regarding the material U.S. federal income tax consequences of owning and disposing of the securities.

Generally, this discussion assumes that you purchased the securities for cash in the original issuance at the stated issue price and does not address other circumstances specific to you, including consequences that may arise due to any other investments relating to an underlier. You should consult your tax adviser regarding the effect any such circumstances may have on the U.S. federal income tax consequences of your ownership of a security.

In the opinion of our counsel, which is based on current market conditions, it is reasonable to treat the securities for U.S. federal income tax purposes as prepaid financial contracts that are “open transactions,” as described in the section entitled “United States Federal Income Tax Considerations—Tax Consequences to U.S. Holders—Securities Treated as Prepaid Financial Contracts that are Open Transactions” in the accompanying product supplement. There is uncertainty regarding this treatment, and the IRS or a court might not agree with it. A different tax treatment could be adverse to you. Generally, if this treatment is respected, (i) you should not recognize taxable income or loss prior to the taxable disposition of your securities (including upon maturity or an earlier redemption, if applicable) and (ii) the gain or loss on your securities should be treated as capital gain or loss.

We do not plan to request a ruling from the IRS regarding the treatment of the securities. An alternative characterization of the securities could materially and adversely affect the tax consequences of ownership and disposition of the securities, including the timing and character of income recognized. In addition, the U.S. Treasury Department and the IRS have requested comments on various issues regarding the U.S. federal income tax treatment of “prepaid forward contracts” and similar financial instruments and have indicated that such transactions may be the subject of future regulations or other guidance. Furthermore, members of Congress have proposed legislative changes to the tax treatment of derivative contracts. Any legislation, Treasury regulations or other guidance promulgated after consideration of these issues could materially and adversely affect the tax consequences of an investment in the securities, possibly with retroactive effect.

Non-U.S. Holders. As discussed under “United States Federal Income Tax Considerations—Tax Consequences to Non-U.S. Holders—Dividend Equivalents under Section 871(m) of the Code” in the accompanying product supplement, Section 871(m) of the Internal Revenue Code and Treasury regulations promulgated thereunder (“Section 871(m)”) generally impose a 30% withholding tax on dividend equivalents paid or deemed paid to Non-U.S. Holders with respect to certain financial instruments linked to U.S. equities or indices that include U.S. equities. The Treasury regulations, as modified by an IRS notice, exempt financial instruments issued prior to January 1, 2027 that do not have a “delta” of one. Based on certain representations made by us, our counsel is of the opinion that Section 871(m) should not apply to the securities with regard to Non-U.S. Holders. Our determination is not binding on the IRS, and the IRS may disagree with this determination.

We will not be required to pay any additional amounts with respect to U.S. federal withholding taxes.

You should consult your tax adviser regarding the U.S. federal income tax consequences of an investment in the securities, including possible alternative treatments, as well as tax consequences arising under the laws of any state, local or non-U.S. taxing jurisdiction.

Additional considerations:

Client accounts over which Morgan Stanley, Morgan Stanley Wealth Management or any of their respective subsidiaries have investment discretion are not permitted to purchase the securities, either directly or indirectly.

Supplemental information regarding plan of distribution; conflicts of interest:

MS & Co. expects to sell all of the securities that it purchases from us to an unaffiliated dealer at a price of $992.50 per security, for further sale to certain fee-based advisory accounts at the price to public of $1,000 per security. MS & Co. will not receive a sales commission with respect to the securities.

MS & Co. is an affiliate of MSFL and a wholly owned subsidiary of Morgan Stanley, and it and other affiliates of ours expect to make a profit by selling, structuring and, when applicable, hedging the securities.

MS & Co. will conduct this offering in compliance with the requirements of FINRA Rule 5121 of the Financial Industry Regulatory Authority, Inc., which is commonly referred to as FINRA, regarding a FINRA member firm’s distribution of the securities of an affiliate and related conflicts of interest. MS & Co. or any of our other affiliates may not make sales in this offering to any discretionary account. See

 Page 12

Morgan Stanley Finance LLC

Dual Directional Trigger PLUS

Principal at Risk Securities

 

“Plan of Distribution (Conflicts of Interest)” and “Use of Proceeds and Hedging” in the accompanying product supplement.

Validity of the securities:

In the opinion of Davis Polk & Wardwell LLP, as special counsel to MSFL and Morgan Stanley, when the securities offered by this pricing supplement have been executed and issued by MSFL, authenticated by the trustee pursuant to the MSFL Senior Debt Indenture (as defined in the accompanying prospectus) and delivered against payment as contemplated herein, such securities will be valid and binding obligations of MSFL and the related guarantee will be a valid and binding obligation of Morgan Stanley, enforceable in accordance with their terms, subject to applicable bankruptcy, insolvency and similar laws affecting creditors’ rights generally, concepts of reasonableness and equitable principles of general applicability (including, without limitation, concepts of good faith, fair dealing and the lack of bad faith), provided that such counsel expresses no opinion as to (i) the effect of fraudulent conveyance, fraudulent transfer or similar provision of applicable law on the conclusions expressed above and (ii) any provision of the MSFL Senior Debt Indenture that purports to avoid the effect of fraudulent conveyance, fraudulent transfer or similar provision of applicable law by limiting the amount of Morgan Stanley’s obligation under the related guarantee. This opinion is given as of the date hereof and is limited to the laws of the State of New York, the General Corporation Law of the State of Delaware and the Delaware Limited Liability Company Act. In addition, this opinion is subject to customary assumptions about the trustee’s authorization, execution and delivery of the MSFL Senior Debt Indenture and its authentication of the securities and the validity, binding nature and enforceability of the MSFL Senior Debt Indenture with respect to the trustee, all as stated in the letter of such counsel dated February 26, 2024, which is Exhibit 5-a to Post-Effective Amendment No. 2 to the Registration Statement on Form S-3 filed by Morgan Stanley on February 26, 2024.

Where you can find more information:

Morgan Stanley and MSFL have filed a registration statement (including a prospectus, as supplemented by the product supplement and the index supplement) with the Securities and Exchange Commission (the “SEC”) for the offering to which this communication relates. You should read the prospectus in that registration statement, the product supplement, the index supplement and any other documents relating to this offering that MSFL and Morgan Stanley have filed with the SEC for more complete information about Morgan Stanley and this offering. When you read the accompanying index supplement, please note that all references in such supplement to the prospectus dated November 16, 2023, or to any sections therein, should refer instead to the accompanying prospectus dated April 12, 2024 or to the corresponding sections of such prospectus, as applicable. You may get these documents without cost by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, MSFL, Morgan Stanley, any underwriter or any dealer participating in the offering will arrange to send you the prospectus, the index supplement and the product supplement if you so request by calling toll-free 1-(800)-584-6837.

Terms used but not defined in this document are defined in the product supplement, in the index supplement or in the prospectus. Each of the product supplement, the index supplement and the prospectus can be accessed via the hyperlinks set forth on the cover of this document.

“Performance Leveraged Upside SecuritiesSM” and “PLUSSM” are our service marks.

 

 Page 13

FAQ

What coupon rate do Citigroup’s Autocallable Phoenix Securities (C) pay?

They offer a 1.4667% monthly contingent coupon, equal to �17.6% annualised, payable only if TMO closes at or above the 85% barrier on each valuation date.

When can the Citigroup note be automatically redeemed?

If on any interim valuation date TMO’s closing price is � $408.28 (initial share price), investors receive $1,000 plus coupon and the note terminates early.

How much principal protection does the note provide?

There is a 15% buffer; below that, losses are magnified at ~117.647% of the decline, so investors can lose their entire investment.

Is the security listed on an exchange?

No. The notes are not exchange-listed; liquidity relies on CGMI making a secondary market, which it may discontinue at any time.

Why is the estimated value ($992.70) lower than the $1,000 issue price?

The difference reflects structuring, hedging and funding costs embedded in the product; it indicates an initial 0.73% premium over economic value.

What are the main tax considerations for U.S. investors?

Citigroup intends to treat the note as a prepaid forward contract with taxable coupon income; treatment is uncertain and could change. Consult a tax adviser.

Do investors receive Thermo Fisher (TMO) dividends during the term?

No. Holders of the notes do not receive dividends or voting rights associated with TMO shares.
Morgan Stanley

NYSE:MS

MS Rankings

MS Latest News

MS Latest SEC Filings

MS Stock Data

224.20B
1.22B
23.64%
62.12%
0.89%
Capital Markets
Security Brokers, Dealers & Flotation Companies
United States
NEW YORK